Form 4: Esperion Therapeutics CEO Sells Shares to Cover Tax Obligations

Esperion Therapeutics CEO Sheldon L. Koenig sold 13,047 shares of common stock on March 18, 2025, at a price of $1.504 per share to satisfy tax obligations related to vested restricted stock units.

Summary

• On March 18, 2025, Sheldon L. Koenig, the President and CEO of Esperion Therapeutics, Inc., sold 13,047 shares of the company's common stock.
• The shares were sold at a price of $1.504 per share.
• The transaction was executed to satisfy tax obligations on vested shares of restricted stock units.
• Following the transaction, Koenig directly owns 1,571,962 shares of Esperion Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock transactions by an insider. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It is common for executives to sell shares to cover tax obligations related to stock-based compensation.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's overall performance.

Key Dates

Keywords

Esperion Therapeutics, Sheldon Koenig, stock sale, Form 4, insider trading, ESPR, restricted stock units, tax obligations